Full Text:   <1679>

Summary:  <1306>

CLC number: R73

On-line Access: 2018-09-04

Received: 2017-04-21

Revision Accepted: 2017-08-29

Crosschecked: 2018-08-27

Cited: 0

Clicked: 3816

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2018 Vol.19 No.9 P.689-698

http://doi.org/10.1631/jzus.B1700219


Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression


Author(s):  Qiao Zou, Yi-Fan Chen, Xiao-Qing Zheng, Suo-Fu Ye, Bin-Yuan Xu, Yu-Xi Liu, Hui-Hui Zeng

Affiliation(s):  State Key Laboratory of Natural and Biomimetic Drugs, Beijing 100191, China; more

Corresponding email(s):   zenghh@bjmu.edu.cn

Key Words:  Butaselen, Signal transducer and activator of transcription 3 (STAT3), Programmed death-ligand 1 (PD-L1), Immunity, Thioredoxin reductase


Qiao Zou, Yi-Fan Chen, Xiao-Qing Zheng, Suo-Fu Ye, Bin-Yuan Xu, Yu-Xi Liu, Hui-Hui Zeng. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression[J]. Journal of Zhejiang University Science B, 2018, 19(9): 689-698.

@article{title="Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression",
author="Qiao Zou, Yi-Fan Chen, Xiao-Qing Zheng, Suo-Fu Ye, Bin-Yuan Xu, Yu-Xi Liu, Hui-Hui Zeng",
journal="Journal of Zhejiang University Science B",
volume="19",
number="9",
pages="689-698",
year="2018",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1700219"
}

%0 Journal Article
%T Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression
%A Qiao Zou
%A Yi-Fan Chen
%A Xiao-Qing Zheng
%A Suo-Fu Ye
%A Bin-Yuan Xu
%A Yu-Xi Liu
%A Hui-Hui Zeng
%J Journal of Zhejiang University SCIENCE B
%V 19
%N 9
%P 689-698
%@ 1673-1581
%D 2018
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1700219

TY - JOUR
T1 - Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression
A1 - Qiao Zou
A1 - Yi-Fan Chen
A1 - Xiao-Qing Zheng
A1 - Suo-Fu Ye
A1 - Bin-Yuan Xu
A1 - Yu-Xi Liu
A1 - Hui-Hui Zeng
J0 - Journal of Zhejiang University Science B
VL - 19
IS - 9
SP - 689
EP - 698
%@ 1673-1581
Y1 - 2018
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1700219


Abstract: 
The thioredoxin system plays a role in a variety of physiological functions, including cell growth, differentiation, apoptosis, tumorigenesis, and immunity. We previously confirmed that butaselen (BS), a novel thioredoxin reductase inhibitor, can inhibit the growth of various human cancer cell lines, yet the underlying mechanism remains elusive. In this study, we investigated the anti-tumor effect of BS in vivo through regulating the immune system of KM mice. We found that BS inhibits tumor proliferation by promoting the activation of splenic lymphocytes in mice. BS can elevate the percentage of CD4CD8+ T lymphocytes and the secretion of downstream cytokines in mice via down-regulating the expression of programmed death-ligand 1 (PD-L1) on the tumor cells’ surface in vivo. Further study in HepG2 and BEL-7402 cells showed that decrease of PD-L1 level after BS treatment was achieved by inhibiting signal transducer and activator of transcription 3 (STAT3) phosphorylation. Taken together, our results suggest that BS has a role in promoting the immune response by reducing PD-L1 expression via the STAT3 pathway, and subsequently suppresses tumorigenesis.

新型硫氧还蛋白还原酶抑制剂丁烷硒啉通过下调PD-L1的表达来抑制肿瘤的发生

目的:评估新型硫氧还蛋白还原酶抑制剂丁烷硒啉(BS)对小鼠免疫系统及肿瘤发生的影响,并初步探讨其作用机制.
创新点:实验室自主设计的硫氧还蛋白还原酶抑制剂BS对免疫系统的调节作用及机制探究.
方法:将24只体重为18~22 g的正常雄性KM小鼠随机分为4组,分别为BS低、中、高剂量组和对照组,每组6只动物.于接种小鼠肝癌H22细胞 (1×106个/只)后第2天开始给药,给药剂量分别为:空白对照组(5 g/L羧甲基纤维素钠(CMC-Na),灌胃(i.g.),每日一次(q.d.));BS低剂量组(90 mg/kg,i.g.,q.d.);BS中剂量组(180 mg/kg,i.g.,q.d.);BS高剂量组(360 mg/kg,i.g.,q.d.).每天观察小鼠状态,连续8天.
结论:BS通过促进小鼠脾淋巴细胞的活化来抑制肿瘤 增殖.BS能够通过下调体内肿瘤细胞表面的程序性死亡配体1(PD-L1)的表达,提高小鼠CD4CD8+ T淋巴细胞百分比和下游细胞因子的分泌.在HepG2和BEL-7402细胞中的进一步研究表明,通过抑制信号传导子及转录激活子3(STAT3)磷酸化,BS处理后PD-L1表达水平降低.综上所述,BS通过STAT3途径降低PD-L1表达,从而产生促进免疫应答的作用,抑制肿瘤发生.

关键词:丁烷硒啉;信号传导子及转录激活子3(STAT3);程序性死亡配体1(PD-L1);免疫;硫氧还蛋白还原酶

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Ahmad SM, Borch TH, Hansen M, et al., 2016. PD-L1-specific T cells. Cancer Immunol Immunother, 65(7):797-804.

[2]Chen J, Jiang CC, Jin L, et al., 2016. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol, 27(3):409-416.

[3]Fang W, Zhang J, Hong S, et al., 2014. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget, 5(23):12189-12202.

[4]Fernandes AP, Capitanio A, Selenius M, et al., 2009. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology, 55(3):313-320.

[5]Godoy-Ramirez K, Franck K, Gaines H, 2000. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J Immunol Methods, 239(1-2):35-44.

[6]Grzywnowicz M, Karczmarczyk A, Skorka K, et al., 2015. Expression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemia. Acta Haematol, 134(4):255-262.

[7]Hassan SS, Akram M, King EC, et al., 2015. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS ONE, 10(9):e0137646.

[8]He J, Li D, Xiong K, et al., 2012. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3 (2H)-ones: organoselenium compounds for cancer therapy. Bioorg Med Chem, 20(12):3816-3827.

[9]Kaimul Ahsan M, Nakamura H, Tanito M, et al., 2005. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med, 39(12):1549-1559.

[10]Lee J, Zhuang Y, Wei X, et al., 2009. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol, 46(2):169-176.

[11]Li Y, Li F, Jiang F, et al., 2016. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci, 17(7):1151.

[12]Lu J, Holmgren A, 2014. The thioredoxin antioxidant system. Free Radic Biol Med, 66:75-87.

[13]Mahmood DF, Abderrazak A, El Hadri K, et al., 2013. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal, 19(11):1266-1303.

[14]Meng X, Huang Z, Teng F, et al., 2015. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev, 41(10):868-876.

[15]Meuillet EJ, Mahadevan D, Berggren M, et al., 2004. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN’s tumor suppressor activity. Arch Biochem Biophys, 429(2):123-133.

[16]Mohler JL, Morris TL, Ford OH 3rd, et al., 2002. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 51(4):247-255.

[17]Nakamura H, Bai J, Nishinaka Y, et al., 2000. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev, 24(1):53-60.

[18]Nomi T, Sho M, Akahori T, et al., 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 13(7):2151-2157.

[19]O'Sullivan KE, Breen EP, Gallagher HC, et al., 2016. Understanding STAT3 signaling in cardiac ischemia. Basic Res Cardiol, 111(3):27.

[20]Siegel RL, Miller KD, Jemal A, 2017. Cancer statistics, 2017. CA Cancer J Clin, 67(1):7-30.

[21]Torre LA, Bray F, Siegel RL, et al., 2015. Global cancer statistics, 2012. CA Cancer J Clin, 65(2):87-108.

[22]Uçeyler N, Göbel K, Meuth SG, et al., 2010. Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Exp Neurol, 222(1):153-160.

[23]Vichai V, Kirtikara K, 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1(3):1112-1116.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE